Cytokinetics ck-274
WebThe REDWOOD-HCM study showed early, sustained efficacy and no serious adverse events with a drug Cytokinetics designed to be superior to mavacamten, a drug it spun … WebMay 6, 2024 · CK-274 is a novel, oral, small molecule cardiac myosin inhibitor arising from an extensive chemical optimization program conducted with careful attention to therapeutic index and pharmacokinetic...
Cytokinetics ck-274
Did you know?
WebJul 19, 2024 · In the trial, CK-274 was generally well tolerated, and no serious adverse events were attributed to CK-274, the company said. Cytokinetics said that the Phase 3 Registrational Trial of CK-274 is ... WebMar 20, 2024 · Drug Profile Aficamten - Cytokinetics Alternative Names: CK 3773274; CK-274 Latest Information Update: 20 Mar 2024 Price : $50 * Buy Profile Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according to local VAT and billing address.
WebAug 29, 2013 · Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness. WebJul 14, 2024 · Cytokinetics is also developing CK-274, a novel cardiac myosin inhibitor that company scientists discovered independent of its collaborations, for the potential …
WebThe preclinical pharmacokinetics of CK-274 were characterized, evaluated and optimized for potential ease-of-use in the clinical setting. A Phase 1 study demonstrated that CK-274 was safe and well tolerated in healthy participants. The pharmacokinetics of CK-274 were generally dose linear, and steady-state appeared evident within 14 days of dosing. WebJul 14, 2024 · In addition to a direct equity investment in Cytokinetics of $50 million at $25.00 per share of common stock, RTW has committed to providing development funding of up to $90M for CK-274, for one or both indications of obstructive and non-obstructive hypertrophic cardiomyopathy, subject to commencement of each pivotal trial by specified …
WebCardiac Myosin Inhibitor, CK-3773274 (CK-274) Cytokinetics Clinical Study: CY 6011 STUDY OBJECTIVES: STUDY DESIGN: Primary: • Determine the safety and tolerability …
WebOct 16, 2024 · Cytokinetics expects to initiate a first-in-human Phase 1 study to assess the safety and tolerability, pharmacokinetics and effect of CK-274 on cardiac function by the end of the year. A potential subsequent Phase 2 clinical study will examine its ability to reduce the left ventricular outflow tract obstruction (LVOTO) in patients with HCM. cat 製品カタログca u4キーエンスWebNov 16, 2024 · Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics continues its over 20-year history of … ca-u5 キーエンスWebPipeline - Cytokinetics A pipeline powered by passion pipeline Research Pre-Clinical Phase 1 Phase 2 Phase 3 CARDIAC MUSCLE Omecamtiv Mecarbil (Heart Failure) Aficamten (oHCM) Aficamten (nHCM) CK-136 … ca u5キーエンスWeb2680 Old Denton Rd, Suite 156, TX 75007. Email: Directions: Give us a call or drop by anytime. We endeavour to answer all enquiries within 24 hours on business days. caught 発音 カタカナWebJan 11, 2024 · CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health … caul smart カウルスマートWebAug 2, 2024 · Cytokineticsis also developing CK-274, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). The … caul smart2 ラディックス